Key statistics
As of last trade Veracyte Inc (12V:DUS) traded at 34.00, -6.08% below its 52-week high of 36.20, set on Nov 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.60 |
---|---|
High | 34.00 |
Low | 33.60 |
Bid | 33.80 |
Offer | 34.80 |
Previous close | 34.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 76.81m |
Free float | 75.50m |
P/E (TTM) | -- |
Market cap | 2.80bn USD |
EPS (TTM) | -0.7444 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 08:30 GMT.
More ▼
Press releases
- Veracyte Announces Third Quarter 2024 Financial Results
- Veracyte to Participate in Upcoming Investor Conferences
- Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
- New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
- New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
- Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
- Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
- Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
More ▼